Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 24


Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cancer.

Cresti N, Lee J, Rourke E, Televantou D, Jamieson D, Verrill M, Boddy AV.

Eur J Cancer. 2016 Mar;55:27-37. doi: 10.1016/j.ejca.2015.10.066. Epub 2016 Jan 8.


Calpain-1 is associated with adverse relapse free survival in breast cancer: a confirmatory study.

Pu X, Storr SJ, Ahmad NS, Chan SY, Moseley PM, Televantou D, Cresti N, Boddy A, Ellis IO, Martin SG.

Histopathology. 2016 Jun;68(7):1021-9. doi: 10.1111/his.12896. Epub 2016 Jan 11.


DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L, Willoughby CE, Televantou D, Thomas HD, Jackson J, Burt AD, Newell D, Rose J, Manas DM, Shapiro GI, Curtin NJ, Reeves HL.

Clin Cancer Res. 2015 Feb 15;21(4):925-33. doi: 10.1158/1078-0432.CCR-14-0842. Epub 2014 Dec 5.


Prognostic significance of the Wnt pathway in squamous cell laryngeal cancer.

Psyrri A, Kotoula V, Fountzilas E, Alexopoulou Z, Bobos M, Televantou D, Karayannopoulou G, Krikelis D, Markou K, Karasmanis I, Angouridakis N, Kalogeras KT, Nikolaou A, Fountzilas G.

Oral Oncol. 2014 Apr;50(4):298-305. doi: 10.1016/j.oraloncology.2014.01.005. Epub 2014 Jan 21.


The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab.

Strimpakos A, Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Andreadou A, Sgouros J, Zizi-Sermpetzoglou A, Kominea A, Televantou D, Razis E, Galani E, Pectasides D, Tejpar S, Syrigos K, Fountzilas G.

Clin Colorectal Cancer. 2013 Dec;12(4):267-274.e2. doi: 10.1016/j.clcc.2013.07.001. Epub 2013 Sep 17.


Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays.

Batistatou A, Televantou D, Bobos M, Eleftheraki AG, Kouvaras E, Chrisafi S, Koukoulis GK, Malamou-Mitsi V, Fountzilas G.

Anticancer Res. 2013 May;33(5):2139-45.


Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.

Fountzilas G, Dafni U, Bobos M, Kotoula V, Batistatou A, Xanthakis I, Papadimitriou C, Kostopoulos I, Koletsa T, Tsolaki E, Televantou D, Timotheadou E, Koutras A, Klouvas G, Samantas E, Pisanidis N, Karanikiotis C, Sfakianaki I, Pavlidis N, Gogas H, Linardou H, Kalogeras KT, Pectasides D, Dimopoulos MA.

BMC Cancer. 2013 Mar 28;13:163. doi: 10.1186/1471-2407-13-163.


Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.

Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Xanthakis I, Sgouros J, Televantou D, Kafiri G, Tsamandas AC, Razis E, Galani E, Bafaloukos D, Efstratiou I, Bompolaki I, Pectasides D, Pavlidis N, Tejpar S, Fountzilas G.

BMC Cancer. 2013 Feb 2;13:49. doi: 10.1186/1471-2407-13-49.


Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis.

Bechmann LP, Vetter D, Ishida J, Hannivoort RA, Lang UE, Kocabayoglu P, Fiel MI, Muñoz U, Patman GL, Ge F, Yakar S, Li X, Agius L, Lee YM, Zhang W, Hui KY, Televantou D, Schwartz GJ, LeRoith D, Berk PD, Nagai R, Suzuki T, Reeves HL, Friedman SL.

J Hepatol. 2013 May;58(5):1000-6. doi: 10.1016/j.jhep.2013.01.020. Epub 2013 Jan 23.


A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.

Karavasilis V, Kotoula V, Pentheroudakis G, Televantou D, Lambaki S, Chrisafi S, Bobos M, Fountzilas G.

J Neurol. 2013 Jun;260(6):1469-80. doi: 10.1007/s00415-012-6812-z. Epub 2013 Jan 5.


Sample parameters affecting the clinical relevance of RNA biomarkers in translational breast cancer research.

Kotoula V, Kalogeras KT, Kouvatseas G, Televantou D, Kronenwett R, Wirtz RM, Fountzilas G.

Virchows Arch. 2013 Feb;462(2):141-54. doi: 10.1007/s00428-012-1357-1. Epub 2012 Dec 20.


DARPP32, STAT5 and STAT3 mRNA expression ratios in glioblastomas are associated with patient outcome.

Televantou D, Karkavelas G, Hytiroglou P, Lampaki S, Iliadis G, Selviaridis P, Polyzoidis KS, Fountzilas G, Kotoula V.

Pathol Oncol Res. 2013 Apr;19(2):329-43. doi: 10.1007/s12253-012-9588-7. Epub 2012 Dec 20.


Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).

Kotoula V, Krikelis D, Karavasilis V, Koletsa T, Eleftheraki AG, Televantou D, Christodoulou C, Dimoudis S, Korantzis I, Pectasides D, Syrigos KN, Kosmidis PA, Fountzilas G.

BMC Cancer. 2012 Aug 6;12:342. doi: 10.1186/1471-2407-12-342.


Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.

Fountzilas G, Dafni U, Bobos M, Batistatou A, Kotoula V, Trihia H, Malamou-Mitsi V, Miliaras S, Chrisafi S, Papadopoulos S, Sotiropoulou M, Filippidis T, Gogas H, Koletsa T, Bafaloukos D, Televantou D, Kalogeras KT, Pectasides D, Skarlos DV, Koutras A, Dimopoulos MA.

PLoS One. 2012;7(6):e37946. doi: 10.1371/journal.pone.0037946. Epub 2012 Jun 5.


Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.

Razis E, Kalogeras KT, Kotoula V, Eleftheraki AG, Nikitas N, Kronenwett R, Timotheadou E, Christodoulou C, Pectasides D, Gogas H, Wirtz RM, Makatsoris T, Bafaloukos D, Aravantinos G, Televantou D, Pavlidis N, Fountzilas G.

Clin Breast Cancer. 2012 Jun;12(3):183-93. doi: 10.1016/j.clbc.2012.03.006. Erratum in: Clin Breast Cancer. 2012 Oct;12(5):386.


Volumetric and MGMT parameters in glioblastoma patients: survival analysis.

Iliadis G, Kotoula V, Chatzisotiriou A, Televantou D, Eleftheraki AG, Lambaki S, Misailidou D, Selviaridis P, Fountzilas G.

BMC Cancer. 2012 Jan 3;12:3. doi: 10.1186/1471-2407-12-3.


Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.

Skarlos P, Christodoulou C, Kalogeras KT, Eleftheraki AG, Bobos M, Batistatou A, Valavanis C, Tzaida O, Timotheadou E, Kronenwett R, Wirtz RM, Kostopoulos I, Televantou D, Koutselini E, Papaspirou I, Papadimitriou CA, Pectasides D, Gogas H, Aravantinos G, Pavlidis N, Arapantoni P, Skarlos DV, Fountzilas G.

Cancer Chemother Pharmacol. 2012 Feb;69(2):533-46. doi: 10.1007/s00280-011-1730-9. Epub 2011 Sep 8.


Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation.

Fountzilas G, Kourea HP, Bobos M, Televantou D, Kotoula V, Papadimitriou C, Papazisis KT, Timotheadou E, Efstratiou I, Koutras A, Pentheroudakis G, Christodoulou C, Aravantinos G, Miliaras D, Petraki K, Papandreou CN, Papakostas P, Bafaloukos D, Repana D, Razis E, Pectasides D, Dimopoulos AM.

Anticancer Res. 2011 Sep;31(9):3007-18. Erratum in: Anticancer Res. 2011 Oct;31(10):3637. Dosage error in article text.


STAT-Related Profiles Are Associated with Patient Response to Targeted Treatments in Locally Advanced SCCHN.

Kotoula V, Lambaki S, Televantou D, Kalogera-Fountzila A, Nikolaou A, Markou K, Misailidou D, Syrigos KN, Fountzilas G.

Transl Oncol. 2011 Feb 1;4(1):47-58.


Simultaneous metastatic papillary thyroid carcinoma and carcinoid of the small intestine in the cervical lymph node group.

Markou KD, Goudakos JK, Triaridis S, Televantou D, Hytiroglou P, Nikolaou A.

Thyroid. 2010 Sep;20(9):1025-8. doi: 10.1089/thy.2009.0438.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk